-
Shanghai Benemae’s Benaglutide Approved by NMPA for Adult Weight Management in China
•
The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by Shanghai Benemae Pharmaceutical Co., Ltd, has been granted approval for adult weight management in China. This marks the second hypoglycemic drug approved for weight loss in the country, following Huadong Medicine Co., Ltd’s (SHE: 000963)…
-
Nanjing Leads Biolabs’ LBL-034 Secures Clinical Trial Approvals from NMPA and FDA
•
Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced receiving clinical trial approvals from both the National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA) for its bispecific antibody (BsAb), LBL-034. The drug targets GPRC5D and CD3 and is intended to treat recurrent/refractory (r/r)…
-
Sanofi to Boost CHC Unit with Full Acquisition of US Health Brand Qunol
•
France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has revealed that it has signed an agreement to fully acquire Qunol, a US-based health and wellness brand. This strategic move is aimed at bolstering Sanofi’s Consumer Healthcare (CHC) unit, enhancing its presence in the consumer health sector. Expanding into the VMS Segment with…
-
AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer
•
AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license agreement with Pfizer (NYSE: PFE), focusing on a portfolio of preclinical gene therapy programs and related enabling technologies. This strategic deal will provide Alexion with access to several novel adeno-associated virus (capsids), which are crucial…
-
AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales
•
UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the first half of 2023, marking another quarter of robust growth in both top-line and bottom-line figures. Global revenues for the six-month period increased by 4% year-on-year (YOY) in constant exchange rate terms to USD 22.295…
-
Sanofi Reports 3.3% YOY Sales Growth in Q2 2023, Driven by Vaccines and Dupixent
•
France-based Sanofi (NASDAQ: SNY) has released its financial results for the second quarter of 2023, reporting a 3.3% year-on-year (YOY) increase in global sales, reaching EUR 9.965 billion (USD 10.98 billion) in constant exchange rate terms. Key growth drivers included sales from vaccines and the anti-allergy drug Dupixent (dupilumab). Dupixent’s…
-
Huadong Medicine Receives NMPA Approval for Phase I Clinical Trial of DR10624 for Weight Management
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study for its Category 1 biologic preparation, DR10624, aimed at weight management for overweight or obese populations. DR10624: A Novel Agonist for Weight…
-
NMPA Seeks Public Input on Strengthening Supervision of Medical Device Contract Manufacturing
•
The National Medical Products Administration (NMPA) is currently seeking public feedback on the “Opinions on Further Strengthening the Supervision of Production Commissioned by Medical Device Registrants (draft proposal)” until August 20, 2023. The initiative aims to fully implement the primary responsibility of medical device registrants for quality and safety, prevent…
